Skip to main content

Table 1 VDIS Subjects Eligible for Antiplatelet Therapy (N = 785)

From: Prevalence of antiplatelet therapy in patients with diabetes

Characteristic

N

Mean or Prevalence

Female

435

55%

Age, mean (SD) (range)

785

64 (11.8) (31–93)

   Age > = 65

395

50%

Race/Ethnicity

  

   White, non-Hispanic

764

97.6%

Education

  

   High school graduate

599

77%

Marital Status

  

   Married or living as married

503

64%

Current smoker

125

16%

Endocrinology consult visit in past year

122

16%

Diabetes education visit in past year

173

23%

Insurance Status *

  

   None

21

2.7%

   Private

472

60.5%

   Medicare

447

57.6%

   Medicaid

143

18.5%

   Military

33

4.3%

Annual household income

  

   < $30,000

407

56.4%

Body Mass Index

  

   Normal (< 25)

85

10.9%

   Overweight (25–29.9)

182

23.4%

   Obese (> = 30)

510

65.6%

Very Obese (> = 40)

141

18.2%

Cardiovascular Disease §

  

   Any CVD

206

26.2%

   Myocardial Infarction

127

16.2%

   Stroke

68

8.7%

   Peripheral Vascular Disease

61

7.8%

Number of prescription medications, mean (SD)

785

6.2 (3.5)

Number of MD visits in previous year, mean (SD)

785

1.5 (2.2)

Years since diagnosis of DM, mean (SD)

785

9.9 (10.1)

Antiplatelet therapy (aspirin or other)

421

53.6%

   Aspirin only

371

47.3%

   Non-aspirin platelet aggregation inhibitor only

20

2.5%

   Aspirin and platelet aggregation inhibitor

30

3.8%

Antiplatelet therapy if known CVD

206

78.2%

  1. * Subjects may have more that one type of insurance coverage
  2. §Subjects may have more than one type of CVD